Dublin, April 14, 2026 (GLOBE NEWSWIRE) — The “Drug Development Services Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The drug development services market has experienced substantial growth and is anticipated to expand from $28.09 billion in 2025 to $31.5 billion in 2026 at a CAGR of 12.2%. This growth is driven by increased R&D investments from pharmaceutical companies, a rise in outsourcing of drug development services, and the prevalence of chronic and infectious diseases. Additionally, advancements in molecular biology and in vitro testing, alongside stricter regulatory compliance requirements, further contribute to this upward trend.
Looking forward, the market is projected to grow to $50.26 billion by 2030 at a CAGR of 12.4%. Key factors bolstering this growth include the adoption of AI and machine learning in drug discovery, expanding biologics and personalized medicine pipelines, and heightened demand for contract research organizations. Emerging market growth for drug development services and the integration of cloud-based clinical data management also play pivotal roles in this expansion.
A significant trend is the growing emphasis on precision and personalized medicine, which customizes medical treatments based on genetic profiles and specific disease conditions. Advances in genomic technologies have heightened the focus on precision medicine, evidenced by the FDA’s approval of 16 new personalized treatments for rare diseases in 2023. Drug development services support this by facilitating targeted therapies’ design, testing, and validation.
Leading companies are innovating by developing solutions like science-driven formulation acceleration platforms to streamline early-stage drug formulation, thereby reducing time-to-market for complex drug candidates. For instance, Aenova Group GmbH launched the Aenovation program in May 2025 to accelerate pharmaceutical formulations’ early development, utilizing a three-step process to improve bioavailability and expedite the journey to clinical trials.
In September 2025, Symeres B.V. expanded its drug development capabilities by acquiring DGr Pharma, enhancing its regulatory expertise and offering a comprehensive end-to-end development platform for biopharmaceutical clients. This expansion highlights the strategic maneuvers companies undertake to bolster service offerings and maintain competitive edges.
The market faces challenges like tariffs impacting the cost of imported laboratory equipment, affecting drug metabolism, medicinal chemistry, and biological services segments. Regions relying on imports, such as North America and Europe, are particularly affected. However, this shift potentially benefits domestic service providers, promoting local sourcing and providing opportunities for regional CROs to enhance service portfolios.
Prominent players in the market include IQVIA Holdings Inc., Labcorp Drug Development, Lonza Group AG, and others. These companies offer specialized services supporting drug discovery, testing, and regulatory approval processes.
Market research reports offer comprehensive insights, encompassing market statistics, competitor analyses, and trends, providing a thorough understanding of the drug development services industry’s current and future landscape.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $31.5 Billion |
| Forecasted Market Value (USD) by 2030 | $50.26 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
Global Drug Development Services Market Trends and Strategies
- Preclinical Research Expansion
- Regulatory Affairs Optimization
- Pharmacovigilance Enhancement
- Clinical Data Management Services Growth
- Quality Assurance and Compliance Services Strengthening
Report Scope:
- Type: Drug Metabolism and Pharmacokinetics, Biological Services, Medicinal Chemistry
- Process: Candidate Validation, Lead Optimization, Target Selection
- Drug: Biologics, Small Molecules
- Therapeutic Area: Cardiovascular, Oncology, Neurology
- End User: Pharmaceutical, Biotechnology, CROs, Research Institutes
Companies Featured
- IQVIA Holdings Inc.
- Labcorp Drug Development
- Lonza Group AG
- SGS Life Sciences
- ICON plc
- Eurofins Scientific SE
- PPD Inc.
- Syneos Health Inc.
- WuXi AppTec Co. Ltd.
- Catalent Inc.
- Charles River Laboratories International Inc.
- Parexel International Corporation
- Samsung Biologics Co. Ltd.
- Medpace Holdings Inc.
- PRA Health Sciences Inc.
- Fujifilm Diosynth Biotechnologies
- Recipharm AB
- PCI Pharma Services Inc.
- Almac Group Limited
- Evotec SE
- Aenova Group GmbH
- Rentschler Biopharma SE
- BioReliance Corporation
- Covance SE
For more information about this report visit https://www.researchandmarkets.com/r/77wuoc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Drug Development Services Market
